公司简介
江阴司特易生物技术公司由数名海归博士创立于2007年12月，主要从事干细胞及生物3D打印技术相关产品的研发和应用，同时根据公司的技术特长，为国内外生物医药企业,科研机构和医院提供干细胞和生物3D打印方面的技术服务。
2008年,司特易公司成为无锡“530”计划扶持的企业，在资金和政策方面受到无锡市政府和江阴经济开发区的大力支持。公司努力吸引管理和技术人才，组建了一个高效的管理团队和技术团队。公司团队充分利用百桥生物园提供的包括中心实验室在内的软、硬件服务，努力研发有自主知识产权的干细胞和生物3D打印相关产品，在十年的时间内获得了丰硕的成果。2009年年初，司特易公司申请到江苏省科技型企业技术创新资金项目，项目编号为SBC200910486。2011年公司与复旦大学共同申请并荣获国家“十二五”重大新药创制项目资助，课题名称“基因重组人源溶菌酶H-LYZ和 LYC4抗耐药性病原菌感染的临床前研究”，课题立项编号2011ZX09102 -007-01。 2008年以来公司与中国科学院魏于全院士进行全面科研合作，共同培养公司在职研究生，在国际、国内干细胞及生物3D打印专业杂志上发表科研论文多篇；并于2014年在江阴组建了院士工作站和干细胞工程研究中心。 2015年与美国生物3D打印公司Allevi（曾用名 BioBots）建立战略合作关系，全面引进生物3D打印技术软、硬件。 同年，公司与江南大学申请并获准成为江苏省研究生培养基地。2016年，公司联手南京大学，南京师范大学，南京航空大学和中国科学院苏州医工所申请并获得江苏省重点科研项目(编号SB2016010)“面向精准医疗的人工髋关节生物三维打印关键技术与成套装备研发”。2016年，公司成功转让“治疗老年黄斑变性（AMD）多肽”项目给北京一上市公司，为江苏省重点项目赢得了足够的配套资金。
经过数年的努力，司特易公司的技术团队全面掌握了包括干细胞的提取，培养，分化，冻存和复苏在内的干细胞相关技术，同时展开了干细胞相关系列产品的研发；我们根据市场需求，研发、生产出了包括EHS水凝胶、ECM包被耗材、LAP蓝光引发剂和FPM滋养蛋白复合物等拳头产品在内的七类30多个产品。在生物3D打印方面， 公司开发出了包括LAP蓝光引发剂，GelMA, HAMA, CSMA, ALMA，ElaMA和ChiMA-LA在内的多种3D打印生物材料（生物墨水）。2012年5月，获得《细胞配对融合芯片》发明专利； 2015年获《颈椎牵引枕》专利证书；2017年8月，递交了4个有关《生物3D打印枪》的专利申请；2018年2月递交《滋养细胞蛋白复合物(FPM)的制备工艺》的专利申请。
司特易公司的服务外包团队承接了来自跨国制药巨头葛兰素史克(GSK),中国医学科学院，清华大学，北京大学，浙江大学，上海交大，四川大学等国内外知名企业和科研院所的外包服务和合作研发项目。通过生物医药的外包服务和合作研发，训练了技术人员，培养了团队精神，这对公司的可持续发展起到了很大的推动作用。
展望未来，任重道远。我们将专注于干细胞和生物3D打印材料（生物墨水）的研发和生产，坚持以人为本、制度为纲、创新为源、产品为先，寻求稳步健康发展。
“路漫漫其修远兮，吾将上下而求索”__屈原。
陈慧敏 MD, PhD
司特易生物 CEO
2018-07-18
StemEasy Introduction
Jiangyin StemEasy Biotechnology Company (StemEasy, SE) has been founded by several returnees from US in December 2007, mainly engaged in stem cell and 3D bioprinting technology related product development and application. Based on the company's expertise, we provide technical service on stem cell and 3D bioprinting for domestic and foreign enterprises, institutes and hospitals.
In 2008, StemEasy became a listed company in "Wuxi “530” Talent Plan, which is a plan to support Western educated returnees going back China to start up enterprises. In early 2009, StemEasy was granted an Innovation Fund from Science and Technology Agency in Jiangsu Province, the project number is SBC200910486. In 2011, jointly with Fudan University, we applied for and was awarded State "the 12 Five-year Plan" Major New Drug Project Fund, the project name is "Recombinant Human lysozyme H-LYZ and LYC4 Preclinical Studies on Anti-drug-resistant Bacteria Infection" and the project number is 2011ZX09102-007-01. Since 2008, our company and Dr. Wei Yuquan, academician of the Chinese Academy of Sciences started our collaboration on scientific research and on-the-job graduate training，co-published a few research papers on stem cell R&D in both domestic and international journals. In 2014, with Dr. Wei’s and Governments support, StemEasy set up the Jiangyin Academician Workstation and Stem Cell Engineering Research Center. In March 2015, we established a cooperation with BioBots, a 3D bio-printing company in US, and introduced their 3D Bio-printing technology and hardware into Chinese market. In 2015, StemEasy become a postgraduate training base of Biotechnology in Jiangsu province. In 2016, the company teamed up with top 3 universities at Nanjing and Suzhou Medical Engineering Research Institute of Chinese Academy of Sciences, to apply for and obtain the funding from Jiangsu Key Technology RD Program（BE2016010）, entitled "Development of key technologies and complete sets of equipment for 3D printing of Hip Prosthesis System toward precision medicine".
After 8 years’ efforts, the StemEasy's technical team masters many technologies related stem cell extraction, amplification, differentiation, cryopreservation and resuscitation. Responding the market demands, we developed a series of products for stem cell research, over 30 products, including EHS Hydrogel, Special-coated cell culture plates and Feeder Protein Mix for hESCs expansion and differentiation. For 3D Bio-printing, the company developed and manufactured LAP (blue light initiator), and a variety of 3D bio-printing materials (Bio ink), e.g. GelMA, HAMA, CSMA and ALMA. Meanwhile, to protect our IP, we apply patents timely. In September 2012, we had our first innovation patent in hand, entitled "Paired Cell Fusion Chip". In 2015, we obtained the patent certificate of "Cervical Traction Pillow"; In August 2017, four patent applications for "the 3D Bioprinting Gun" were submitted. In February 2018, the patent application for "the Preparation Process of Feeder Protein Mix (FPM) " was submitted.
StemEasy also provides technical services for multinational pharmaceutical companies, e.g. GSK R&D Center in China, Novartis R&D Center, Qinhua University, Beijing University, Zhejiang University, Sichuan University, and the Tianjin International Biomedical Joint Academy. Through outsourcing and collaboration, we accumulate R&D experiences and buildup our own expertise, which significantly promotes our company’s sustainable progress.
Looking to the future, we will insist our R&D mission on stem cell and 3D bioprinting material in China, adhere to people foremost, manage company by rules, innovation as the source, product first, and expand our business actively in a steady and healthy pace.
"The road is long, we’ll persist to look for ultimate truth." __ by Qu Yuan, a Chinese poet.
Harry Huimin Chen, M.D., Ph.D
StemEasy Bio, CEO
July 17, 2018
